DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Infant Severe Sepsis and Bacterial Meningitis in Malawi

Information source: University of Malawi College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infant Bacterial Meningitis

Intervention: Ceftriaxone v penicillin and gentamicin (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: University of Malawi College of Medicine

Official(s) and/or principal investigator(s):
Elizabeth Molyneux, FRCPCH, Principal Investigator, Affiliation: Malawi College of Medicine, Paediatrics Department

Summary

This study aims to improve the outcome of infants (<2 months) with severe sepsis and meningitis at the Queen Elizabeth Central Hospital, Blantyre, Malawi. Currently WHO recommends the treatment of infant severe sepsis and bacterial meningitis with 14 to 21 day course of penicillin and gentamicin as first line. The second line treatment is cefotaxime or ceftriaxone. Severe bacterial infections are common in infants under 2 months of age and the mortality is very high (~50%). There are several reasons for this; one is that the first line antibiotics used are no longer as effective as they used to be. Bacterial resistance to the first line antibiotics has increased and some infections especially of the central nervous system may only be partly treated and not eradicated by present therapy. First line treatment is cheap and available but requires 4 injections a day, for at least 14 days, a total of 58 injections. Many mothers find this number too much and abscond. The investigators second line therapy is ceftriaxone which is also available and cheap and the advantage of being given as a daily injection. The disadvantage is that it can cause (reversible) jaundice particularly in premature babies and it must not be given with calcium products. The investigators do not give calcium to the investigators infants as the investigators cannot routinely check electrolytes. All the most common causes of bacterial meningitis in this age group in the investigators setting are sensitive to ceftriaxone. The investigators wish to undertake an open randomized trial of penicillin and gentamicin v ceftriaxone as first line treatment for infant meningitis. The investigators are able to monitor for side effects. The investigators hypothesise that the ceftriaxone arm will have 20% less deaths that the penicillin and gentamicin group.

Clinical Details

Official title: An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Recovery v death or severe residual neurological sequelae at hospital discharge, 1 month and 6 months post discharge.

Secondary outcome: Outcome by causative bacterial agent, recovery v death or severe residual neurological sequelae at hospital discharge, 1 month and 6 months post discharge.

Eligibility

Minimum age: N/A. Maximum age: 2 Months. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Children less than 2 months

- Suspicion of bacterial meningitis

- Parental/guardian informed consent

Exclusion Criteria:

- Infant with hyperbilirubinaemia

- Infant requiring calcium

- Infant know to be hypersensitive to any of the three drugs

- Infant who has been an inpatient for more than 72 hours

- Infant with congenital central nervous system abnormalities

Locations and Contacts

Queen Elizabeth Central Hospital/ College of Medicne, Private Bag 360 Blantyre 3, Malawi
Additional Information

Starting date: April 2010
Last updated: January 15, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017